Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica.
Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, Ogino M, Yokota T, Miyamoto K, Niino M, Nomura K, Tomioka R, Tanaka M, Kawachi I, Ohashi T, Kaida K, Matsui M, Nakatsuji Y, Ochi H, Fukaura H, Kanda T, Nagaishi A, Togo K, Mizusawa H, Murai H, Kira J. Yamasaki R, et al. Among authors: fukaura h. Mult Scler. 2016 Sep;22(10):1337-48. doi: 10.1177/1352458515617248. Epub 2015 Nov 12. Mult Scler. 2016. PMID: 26564994
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Among authors: fukaura h. Lancet Neurol. 2020 Apr;19(4):298-306. doi: 10.1016/S1474-4422(20)30066-1. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199095 Clinical Trial.
HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data.
Watanabe M, Nakamura Y, Sato S, Niino M, Fukaura H, Tanaka M, Ochi H, Kanda T, Takeshita Y, Yokota T, Nishida Y, Matsui M, Nagayama S, Kusunoki S, Miyamoto K, Mizuno M, Kawachi I, Saji E, Ohashi T, Shimohama S, Hisahara S, Nishiyama K, Iizuka T, Nakatsuji Y, Okuno T, Ochi K, Suzumura A, Yamamoto K, Kawano Y, Tsuji S, Hirata M, Sakate R, Kimura T, Shimizu Y, Nagaishi A, Okada K, Hayashi F, Sakoda A, Masaki K, Shinoda K, Isobe N, Matsushita T, Kira JI. Watanabe M, et al. Among authors: fukaura h. Sci Rep. 2021 Jan 12;11(1):607. doi: 10.1038/s41598-020-79833-7. Sci Rep. 2021. PMID: 33436735 Free PMC article.
Correlation of the symbol digit modalities test with the quality of life and depression in Japanese patients with multiple sclerosis.
Niino M, Fukumoto S, Okuno T, Sanjo N, Fukaura H, Mori M, Ohashi T, Takeuchi H, Shimizu Y, Fujimori J, Kawachi I, Kira JI, Takahashi E, Miyazaki Y, Mifune N. Niino M, et al. Among authors: fukaura h. Mult Scler Relat Disord. 2022 Jan;57:103427. doi: 10.1016/j.msard.2021.103427. Epub 2021 Nov 24. Mult Scler Relat Disord. 2022. PMID: 34861614
Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.
Tahara M, Oeda T, Okada K, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H. Tahara M, et al. Among authors: fukaura h. Mult Scler Relat Disord. 2022 Apr;60:103730. doi: 10.1016/j.msard.2022.103730. Epub 2022 Mar 7. Mult Scler Relat Disord. 2022. PMID: 35287025 Free article. Clinical Trial.
37 results